NNVC - NanoViricides, Inc. News

NanoViricides Advances NV-387 Measles Treatment Toward Phase II Trials Following FDA Rare Pediatric

NanoViricides, Inc., a publicly traded company (NYSE:NNVC) (the "Company"), and a clinical s

While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for

SHELTON, CT / ACCESS Newswire / August 31, 2026 / NanoViricides, Inc., a publicly traded company (NY

World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Cri

https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidem

defenseworld.net

NanoViricides (NYSE:NNVC) Trading Down 2.2% – Time to Sell?

NanoViricides, Inc. (NYSE: NNVC - Get Free Report)'s stock price dropped 2.2% during mid-day trading

NanoViricides Announces Expects Its Phase II Clinical Trial Of NV-387 Oral Gummies To Treat Bundibug

Under the leadership of Professor Katoto, NanoViricides, as the drug sponsor of NV-387 Oral Gummies,

The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the

SHELTON, CT / ACCESS Newswire / August 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Co

NanoViricides Wins DRC Approval To Begin Phase II Trial Of NV-387 Oral Gummies For Ebola

NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antivira

NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies

SHELTON, CT / ACCESS Newswire / August 10, 2026 / NanoViricides, Inc. (NYSE American: NNVC ) (the "C

NanoViricides Awaits Regulatory Approval To Begin Phase II Clinical Trial Of NV-387 Oral Gummies As

NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antivira

NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-38

SHELTON, CT / ACCESS Newswire / July 28, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Compa

12 Health Care Stocks Moving In Friday's Pre-Market Session

Gainers Advanced Biomed (NASDAQ:ADVB) shares moved upwards by 28.3% to $21.53 during Friday's p

NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering

SHELTON, CT / ACCESS Newswire / July 24, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoViric

NanoVricides Applies To DRC Regulatory Agency ACOREP For Approval To Begin A Phase II Clinical Trial

NanoViricides has retained Om Sai Clinical Research Private Limited, India, as the CRO for this Phas

NanoViricides Gets National Ethics Committee Approval For Phase II Clinical Study Of NV-387 Oral Gum

NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antivira

As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approva

SHELTON, CT / ACCESS Newswire / July 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Compa

Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" I

SHELTON, CT / ACCESS Newswire / July 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Compan

Noble Capital Markets Initiates Coverage On Nanoviricides with Outperform Rating, Announces Price Ta

Noble Capital Markets analyst Robert LeBoyer initiates coverage on Nanoviricides (AMEX:NNVC) with

NanoViricides Continues To Advance Broad-Spectrum Antiviral Drug NV-387 Towards Phase II Clinical Tr

NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antivira

As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Or

SHELTON, CT / ACCESS Newswire / July 6, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Compan

FDA's Office Of Orphan Products Development Grants Rare Pediatric Disease Drug Designation To NanoVi

NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a c

US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles

SHELTON, CT / ACCESS Newswire / June 29, 2026 / NanoViricides, Inc., a publicly traded company (NYSE

NanoViricides Ships NV-387 Oral Gummies To The Democratic Republic of Congo Ahead Of Patient Enrollm

Clinical Trial Site preparations are being performed by our CRO in India, Om Sai Clinical Research P

NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo

SHELTON, CT / ACCESS Newswire / June 22, 2026 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"

NanoViricides' Proposal To Perform Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For C

NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antivira

As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment

SHELTON, CT / ACCESS Newswire / June 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Compa

NanoViricides Proposes Phase II Clinical Study Of NV-387 Oral Gummies To Congo To Treat Current Bund

NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing

As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial

SHELTON, CT / ACCESS Newswire / June 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Compan

NanoViricides Files Prospectus For Offering $50M Mixed Shelf

https://www.sec.gov/Archives/edgar/data/1379006/000110465926071007/tm2616485d1_s3.htm

12 Health Care Stocks Moving In Wednesday's Intraday Session

Why Semtech Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket

Semtech Corp (SMTC) reported strong Q1 financial results, beating analysts' estimates. Shares ro

In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatme

SHELTON, CT / ACCESS Newswire / May 26, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Compan

NanoViricides closes $2M direct offering

NanoViricides (NYSE-A:NNVC) announced the closing of its previously disclosed registered direct offe

NanoViricides closes $2M direct offering

NanoViricides (NYSE-A:NNVC) announced the closing of its previously disclosed registered direct offe

Nasdaq semis lead losses as bond yields put pressure on Iran talks

10am: Nasdaq semiconductors lead early decline Selling dominated early trading in New York on Tuesd

NanoViricides Announces Closing of ~$2 Million Registered Direct Offering

SHELTON, CT / ACCESS Newswire / May 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) ("NanoVirici

Cyclical stocks' strong run may be due a pause despite leading markets this year, leading bank warns

Cyclical stocks, value shares and small caps have led European and US markets so far this year in a

NanoViricides says its broad-spectrum antiviral could help tackle Ebola strain behind Congo outbreak

NanoViricides (NYSE-A:NNVC), the US clinical-stage drugmaker, has said its lead drug candidate NV-38

NanoViricides Prices Sale Of 1,333,334 Shares And Warrants For Gross Proceeds Of ~$2M

NanoViricides, Inc. (NYSE:NNVC) ("NanoViricides" or the "Company"), a clinical stage

NanoViricides' Clinical Stage, Broad-Spectrum, Antiviral Drug NV-387 Granted Orphan Drug Designation

NanoViricides, Inc., a publicly traded company (NYSE:NNVC) (the "Company"), and a clinical s

NanoViricides Granted FDA Orphan Drug Designation Status For Treatment Of The Measles Virus

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1140226

NanoViricides Files Application For Rare Pediatric Disease Drug Designation For NV-387 As Treatment

NanoViricides, Inc., a publicly traded company (NYSE:NNVC) (the "Company"), and a clinical s

NanoViricides To Launch Phase II Trial Of NV-387 For Monkeypox Clade I In DRC, Targeting Pandemic-Re

NanoViricides, Inc. (NYSE:NNVC) (the "Company") today announced that a Phase II Clinical Tri

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Nanoviricides Q2 EPS $(0.11) Beats $(0.14) Estimate

Nanoviricides (AMEX:NNVC) reported quarterly losses of $(0.11) per share which beat the analyst cons

NanoViricides Files Application For Orphan Drug Designation For NV-387 To Treat Measles

NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a c

NanoViricides Signs Master Services Agreement With Only Orphans Cote To Advance Orphan Drug Strategy

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clin

12 Health Care Stocks Moving In Monday's After-Market Session

12 Health Care Stocks Moving In Tuesday's After-Market Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session